Yahoo · Sep 1, 2026
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
NASDAQ · DHR
Danaher Corporation
Healthcare · Medical - Diagnostics & Research
$209.91
Up+$3.01 (+1.46%)
Updated Sep 3, 2026, 5:00 AM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 166.5B
- P/E ratio
- 47.14
- Dividend yield
- 0.59%
- 52-week range
- $160.93 – $242.80
- Volume
- 2.95M
- Avg. volume
- 4.18M
Price performance
DHR price history
1M range · 21 trading sessions · Daily adjusted prices
DHR closed at $209.91 after 21 trading sessions, up 5.13% for the selected period.
- Last close
- $209.91
- Period change
- +5.13%
- Period low
- $199.58
- Period high
- $218.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $207.77 | $212.7793 | $206.10 | $209.91 | 2.95M |
| Sep 1, 2026 | $214.74 | $215.00 | $206.55 | $206.93 | 3.15M |
| Aug 31, 2026 | $213.45 | $215.385 | $212.22 | $213.56 | 3.61M |
| Aug 28, 2026 | $215.10 | $217.04 | $212.8502 | $216.07 | 2.86M |
| Aug 27, 2026 | $214.78 | $218.57 | $213.092 | $215.68 | 2.93M |
| Aug 26, 2026 | $213.23 | $216.8499 | $212.81 | $215.36 | 2.53M |
| Aug 25, 2026 | $213.88 | $216.77 | $212.24 | $215.97 | 2.34M |
| Aug 24, 2026 | $218.33 | $218.34 | $213.88 | $215.11 | 2.51M |
| Aug 21, 2026 | $215.58 | $220.25 | $213.46 | $218.85 | 4.7M |
| Aug 20, 2026 | $210.12 | $220.67 | $208.21 | $215.91 | 5.5M |
| Aug 19, 2026 | $203.10 | $212.19 | $202.905 | $211.50 | 5.25M |
| Aug 18, 2026 | $203.97 | $204.23 | $199.49 | $199.58 | 2.29M |
| Aug 17, 2026 | $199.99 | $203.43 | $199.99 | $202.63 | 2.98M |
| Aug 14, 2026 | $203.00 | $203.96 | $201.12 | $202.45 | 2.24M |
| Aug 13, 2026 | $207.06 | $207.4899 | $202.17 | $203.89 | 1.92M |
| Aug 12, 2026 | $204.55 | $207.59 | $202.00 | $205.79 | 3.04M |
| Aug 11, 2026 | $208.05 | $208.44 | $206.0901 | $207.44 | 2.47M |
| Aug 10, 2026 | $203.26 | $209.37 | $200.78 | $209.37 | 3.68M |
| Aug 7, 2026 | $199.40 | $205.19 | $198.435 | $204.76 | 3.32M |
| Aug 6, 2026 | $199.96 | $201.3425 | $196.48 | $199.98 | 2.79M |
| Aug 5, 2026 | $195.60 | $201.24 | $193.30 | $199.66 | 3.75M |
Latest DHR news
The latest Smart Investors Daily articles mentioning DHR.
Stock researchCompany · Overview
DHR research
Overview
Company profile and research snapshot.
Company profile
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $249.71
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2026 | RBC Capital | Outperform | — |
| Jul 22, 2026 | Guggenheim | Buy | — |
| Jul 22, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | TD Cowen | Buy | — |
| Jul 22, 2026 | Wells Fargo | Equal-Weight | — |
News briefing
Generated Sep 2, 2026, 9:09 PM
Why Is DHR Up Today?
Danaher Corporation gained $3.01 (1.46%) in today's trading, reflecting a modest positive momentum despite broader market dynamics. The stock's movement comes amid questions about its relative performance versus the Nasdaq, suggesting investors are reassessing DHR's positioning within the current market environment.
Bottom line: DHR's modest 1.46% gain today provides limited clarity on the stock's trajectory, with underlying analyst concerns about relative Nasdaq underperformance suggesting investors should monitor execution metrics closely. The key for investors will be whether management can demonstrate renewed growth momentum and margin expansion to justify valuations relative to technology peers.
Yahoo · Aug 31, 2026
Is Danaher Stock Underperforming the Nasdaq?
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Yahoo · Aug 28, 2026
Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
Yahoo · Aug 28, 2026
Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
AI research layers
Interpretive context generated from the platform’s current data sources.
Danaher Corporation Stock Performance
Danaher Corporation shares closed at $206.93, declining 1.12% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated strong near-term momentum, gaining 9.53% over the past month and 18.73% over the trailing three months. However, the one-year return remains negative at -5.97%, indicating that recent strength has only partially recovered longer-term losses. Technically, DHR trades above both its 50-day moving average of $199.70 and its 200-day moving average of $200.50, suggesting a constructive trend structure. The 14-day RSI reads 58.5, placing the stock in neutral territory without overbought or oversold conditions. Danaher's beta of 0.923 reflects slightly lower volatility relative to the broader market. Average daily trading volume stands at approximately 4.18 million shares, according to Massive/Polygon data, supporting adequate liquidity for institutional positioning. The current market capitalization is approximately $166.5 billion.
Danaher Corporation Valuation Analysis
Danaher Corporation currently trades at a price-to-earnings ratio of 47.14, a significant premium relative to the broader Healthcare sector, per SID market data. The PEG ratio stands at 14.87, suggesting that the elevated earnings multiple is not fully supported by near-term growth expectations. The price-to-book ratio of 3.23 reflects the market's recognition of Danaher's asset-light, high-margin business model and its portfolio of differentiated life sciences and diagnostics platforms. The company offers a modest dividend yield of approximately 0.53%, according to SEC filings, positioning it as a growth-oriented holding rather than an income investment. Danaher's $166.5 billion market capitalization places it among the largest diversified healthcare companies globally. The premium valuation metrics indicate the market is pricing in sustained long-term earnings expansion, likely driven by its Danaher Business System operational framework and recurring revenue streams across its biotechnology and diagnostics segments.
Smart Money Activity for DHR
Danaher Corporation's composite smart money score stands at 51, reflecting a neutral overall signal, per SID market data. The institutional sub-score registers a perfect 25 out of 25, indicating maximum institutional conviction and robust accumulation by large asset managers, according to 13F institutional filings. Notably, insider activity has been heavily skewed toward purchases, with 17 insider buys versus only 3 insider sells across 20 total transactions in the last 90 days, per SEC Form 4 filings. This 5.7-to-1 buy-to-sell ratio represents a meaningful bullish signal from corporate insiders with direct knowledge of the company's operations and pipeline. The insider sub-score of 4.9 out of 25, however, suggests these purchases may be relatively modest in dollar terms. The dark pool activity sub-score of 8.5 out of 25 indicates moderate off-exchange trading interest. Congressional trading activity scored 12.8 out of 25, reflecting middling legislative portfolio exposure. The divergence between strong institutional conviction and more moderate alternative signals warrants monitoring.
Danaher Corporation Earnings Outlook
Danaher Corporation has delivered consistent earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $1.94 against analyst estimates of $1.84, representing a $0.10 positive surprise. The prior quarter saw EPS of $2.06 versus estimates of $1.94, a $0.12 beat that marked the largest surprise in the reported period. The quarter before that produced EPS of $2.23 against consensus of $2.17, a $0.06 upside surprise. This pattern of sequential beats reflects disciplined execution and potentially conservative management guidance. The upcoming quarter carries an analyst consensus estimate of $2.17 per share, per analyst estimates. The three-quarter trend of exceeding expectations by an average of approximately $0.09 per share suggests management maintains a track record of operational outperformance relative to Wall Street models, though the sequential decline in reported EPS warrants attention.
Wall Street Analyst Ratings for DHR
Wall Street coverage of Danaher Corporation reflects a predominantly constructive outlook, per SID consensus data. In the most recent round of analyst updates on July 22, 2026, four out of five covering analysts maintained positive ratings. TD Cowen, Stifel, and Guggenheim each reiterated Buy ratings, while RBC Capital maintained its Outperform designation, according to Wall Street analyst reports. Wells Fargo was the sole neutral voice, reiterating its Equal-Weight rating. Notably, none of the five analysts changed their ratings following the most recent earnings release, suggesting the quarterly results aligned with their existing investment theses. The absence of any downgrades or upgrades indicates a stable consensus view. The 80% bullish coverage ratio — four positive ratings out of five — reflects broad confidence in Danaher's strategic positioning within the life sciences and diagnostics markets. The concentration of reaffirmations rather than initiations suggests these analysts have maintained long-standing coverage with established price frameworks for the stock.
